AlphaMedix not checked
Orano Med LLC · Pb212-octreotide analog
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors”In the company’s words, NCT05153772 on ClinicalTrials.gov
- Tested for
- Neuroendocrine Tumors
- Main trialPhase 2
- “Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with either no prior history of peptide receptor radionuclide therapy (PRRT naive) or prior history of peptide receptor radionuclide therapy (Previous PRRT)”In the company’s words, NCT05153772 on ClinicalTrials.gov
- Other names
- Pb212-octreotide analog
Other drugs for Neuroendocrine Tumors
- CAM2029Camurus AB · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 14 Apr 2025 | Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients | |
| Phase 1Terminated | 6 Apr 2023 | Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026